Enrollment is now getting underway in tests of several new investigational drug therapies for COVID-19, the National Institutes of Health recently announced. The four trials will recruit adults over 18 who are experiencing mild to moderate symptoms of the virus, but do not require hospitalization.
Three Missouri sites are participating in the trials, including Washington University in St. Louis; the University of Missouri Health Care System in Columbia, and the Hannibal Clinic in Hannibal.
The trials are part of the ongoing ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) program that began last August. Launched under the umbrella of Operation Warp Speed, the program is a public-private research partnership formed to accelerate the development and distribution of the most promising new treatments and vaccines to combat the virus.
The trial’s current phase, called ACTIV-2, will test four potential treatments for safety and efficacy. Enrollment in the first study of SNG001, an inhalable drug delivered by nebulizer, began on Feb. 10, with studies of the other potential treatments expected to begin enrolling participants soon.
To qualify for ACTIV-2, participants must have tested positive for COVID-19 within 10 days and have started experiencing symptoms within eight days of enrolling.
More information about the ACTIV-2 trials, including how to inquire about participating in a study, is available at riseabovecovid.org.